BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials is drawing significant interest across the industry.
**media[930610]**BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world's first dual-payload antibody-drug conjugate (ADC) to enter clinical development.BioDlink enabled IND approval 1.5 months ahead of schedule through efficient process development, manufacturing, and analytical execution.SUZHOU, China, Feb. 9, 2026 /PRNewswire/ -- BioDlink announced that it has received a formal letter of appreciation from its client, Chengdu Kanghong Pharmaceutical Group ('Kanghong Pharmaceutical'), recognizing BioDlink's critical contribution to the successful clinical approval of KH815, the world's first dual-payload antibody-drug conjugate (ADC) to enter clinical development. KH815 is a first-in-class dual-payload ADC independently developed by Kanghong Pharmaceutical. The program achieved a major regulatory milestone with approval from Australia's Human Research Ethics Committee (HREC) on March 21, 2025 followed by clinical trial authorization in China on April 15, 2025.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Pokémon Pokopia review: Possibly the most charming Pokémon game yet
- Gadgets Now Awards 2025: Winners of Editors’ Choice category
- RJD Kerala chief Shreyams Kumar quits electoral politics, says decision final
- Gulf tensions: Will use every policy tool to help exporters, assures Piyush Goyal
Source: Original →